셀트리온제약

068760KOSDAQ의약품 제조업

50.8 / 100

Reference Date: 2026-06-10

Financial Score20.5 / 40

News Sentiment16.3 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but PER raises overvaluation concerns. Plunged 22.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Celltrion Pharma is a pharmaceutical company with KGMP, U.S. cGMP, and EU-GMP certifications, producing specialty and biopharmaceuticals at facilities in Jincheon and Ochang, South Korea. Key products include the liver disease treatment 'Godeks' and biosimilars such as 'Ramsima', 'Omlizumab', 'Stelizumab', and 'Aducanumab'. Sales in 2024 rose 22.9% year-on-year to 4.778 trillion KRW.

Number of Employees

1,006people

Average Salary

77.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

47.81Industry Average 11.930.0Point

4.0x industry avg (risky)

PBR

4.34Industry Average 0.890.0Point

4.9x industry avg (risky)

ROE

9.31Industry Average 4.017.0Point

2.3x industry avg (excellent)

Debt Ratio

9.14Industry Average 12.435.0Point

Lower than industry avg (good)

Trend 2023~20258.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲17.6% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲26.9% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 6.9% (improving, 3yr)

Detailed News Sentiment

7 totalPositive 3Neutral 4Negative 0Average Sentiment Score 65

Neutral
규제 임박 중복상장...거래소 "기업 작다고 주주보호 기준 달라선 안....
거래소의 중복상장 규정 개선 세미나 진행 중, 구체적인 셀트리온제약 영향은 제한적.
Neutral
“중복상장시 이해관계 없는 '특별위원회' 구성해 주주보호해야”
중복상장 관련 제도 개선 논의는 셀트리온제약 직접적 영향이 적어 중립적 평가.
Neutral
중복상장 때 모회사 일반주주 동의 필요…"투자자 보호"
금융당국의 중복상장 규제 강화 방안 발표로 셀트리온제약 모회사 주주 동의 의무화 논의 중, 직접적인 영향은 제한적.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 42,650Won52-week high 75,70052-week low 42,650

1-month return0.0Point

1m -22.31% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]2026-06-01
Neutral분기보고서 (2026.03)2026-05-15